Can a blood thinner boost vision after retinal detachment surgery?
NCT ID NCT07787377
First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time
Summary
This trial tests whether adding enoxaparin (Clexane) to the fluid used during vitrectomy surgery can improve vision in people with retinal detachment complicated by proliferative vitreoretinopathy (PVR), a condition where scar-like tissue forms on the retina. About 60 adults aged 18-65 will have standard vitrectomy, with half receiving enoxaparin during the procedure and half not. The study compares visual acuity before and after surgery to see if enoxaparin's anti-inflammatory effects lead to better outcomes.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Enoxaparin sodium (Clexane) added to the infusion fluid during pars plana vitrectomy surgery
- What this could lead to
- If it works, adding enoxaparin during surgery could reduce harmful inflammation and improve vision recovery after retinal detachment repair.
- What could go wrong
- This is a small, early-stage study, and the benefit is uncertain. Enoxaparin is a blood thinner, so it may raise bleeding risks during or after surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
60 people
The number who actually took part.
- Started
-
May 2026
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male or female patients aged 18-65 years. * Rhegmatogenous retinal detachment with grade C proliferative vitreoretinopathy in the study eye. * Patients with a clear crystalline lens or pseudophakia in the study eye. Exclusion Criteria: * Giant retinal tear in the study eye measuring more than 3 clock hours. * Patients scheduled for combined pars plana vitrectomy and cataract surgery for retinal detachment repair in the study eye. * Chronic inflammatory condition involving the study eye. * History of perforating or non-perforating ocular trauma in the study eye. * Cataract surgery within the preceding 3 months in the study eye. * Previous retinal procedures in the study eye within the preceding 6 months, including laserpexy, cryopexy, intravitreal gas injection, anti-vascular endothelial growth factor injection, or corticosteroid injection. * Single-eyed patients, defined in the synopsis as having best-corrected visual acuity in the fellow eye of \>1.0 logMAR, \<0.1 decimal, \<1/10, or \<6/60 Snellen fraction.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Rhegmatogenous retinal detachment with grade C proliferative vitreoretinopathy are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lahore General Hospital, Lahore
Lahore, Punjab Province, 54000, Pakistan